Glenmark Pharmaceuticals Analyst Review May 2026
- May 20, 2026
- Posted by: Neeraj Pandey
- Category: News
This Glenmark Pharmaceuticals analyst review for May 2026 covers the key data investors need for GLENMARK at its current price of Rs 2,324.10. Glenmark Pharmaceuticals (NSE: GLENMARK) is a leading global pharma company with a market capitalisation of approximately Rs 65,000 crore, known for respiratory, dermatology, and oncology drugs. The analyst consensus target of Rs 2,800 implies meaningful upside, and this Glenmark Pharmaceuticals analyst review examines technical levels, business performance, valuation, and key risks that will determine whether GLENMARK achieves that target through FY27.
Click Here – Get Free Investment Predictions
Glenmark Pharmaceuticals Company Snapshot May 2026
Glenmark’s innovative R&D pipeline (Ryaltris nasal spray, GRC 17536 pain molecule, ISB 880 anti-IL-33 antibody) differentiates it from pure generic-focused peers. A strong US generics business adds base revenue stability. The table below summarises the key data referenced in this Glenmark Pharmaceuticals analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | GLENMARK |
| Sector | Pharmaceuticals – Branded and Specialty |
| CMP (May 2026) | Rs 2,324.10 |
| 52 Week High | Rs 2,474.00 |
| 52 Week Low | Rs 1,370.00 |
| Market Cap | Rs 65,000 Crore |
| Trailing P/E | 18x |
| Analyst Consensus Target | Rs 2,800 |
| Bull Case Target | Rs 3,400 |
| Bear Case Target | Rs 2,000 |
Analyst Insight in This Glenmark Pharmaceuticals Analyst Review
Associate Director Kunal Singla suggests watching Glenmark Pharmaceuticals closely in May 2026. At Rs 2,324.10, Kunal Singla flags Pharmaceuticals – Branded and Specialty sector dynamics as the primary driver for GLENMARK’s near-term price action. He notes support in the Rs 1397 to Rs 2208 zone and flags any sustained close above Rs 2464 as a positive signal worth tracking. Kunal Singla’s perspective on Glenmark Pharmaceuticals adds professional analysis to this Glenmark Pharmaceuticals analyst review and is not a buy recommendation.
Technical Analysis in This Glenmark Pharmaceuticals Analyst Review
At Rs 2,324.10, GLENMARK is trading within its 52-week band of Rs 1,370.00 to Rs 2,474.00. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 1397 to Rs 2208 band while resistance is seen in the Rs 2464 to Rs 2562 zone. A sustained move above Rs 2464 could open the path toward the analyst consensus target of Rs 2,800.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 1397 to Rs 2208 – investors tracking this Glenmark Pharmaceuticals analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for GLENMARK.
- Resistance Zone: Rs 2464 to Rs 2562 – a sustained close above Rs 2464 would be a positive breakout signal worth flagging in this Glenmark Pharmaceuticals analyst review.
- Medium-Term Target: The analyst consensus of Rs 2,800 represents the base-case upside scenario identified in this Glenmark Pharmaceuticals analyst review.
Business Segment Analysis
Branded Formulations (Respiratory and Dermatology)
This is the primary revenue and margin driver for Glenmark Pharmaceuticals, directly supporting the earnings trajectory toward the consensus target of Rs 2,800.
US Generics (Dermatology and Controlled Substances)
This segment adds scale and diversification to Glenmark Pharmaceuticals’s business model and is a meaningful EPS contributor through FY27 and FY28.
Innovative R&D Pipeline (Novel Molecules)
This represents the medium-term growth frontier for Glenmark Pharmaceuticals and a key re-rating catalyst for the stock over the next 12 to 24 months.
Valuation in This Glenmark Pharmaceuticals Analyst Review
At Rs 2,324.10, Glenmark Pharmaceuticals trades at a trailing P/E of 18x. This Glenmark Pharmaceuticals analyst review presents three valuation scenarios: a bull case of Rs 3,400 on strong earnings delivery and sector tailwinds, a base case of Rs 2,800 at analyst consensus, and a bear case of Rs 2,000 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Glenmark Pharmaceuticals analyst review.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 3,400 | Strong earnings delivery and sector re-rating |
| Base Case (Consensus) | Rs 2,800 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 2,000 | Earnings miss or macro headwinds |
Trade Outlook for Glenmark Pharmaceuticals
Based on the technical and fundamental analysis in this Glenmark Pharmaceuticals analyst review, investors might watch GLENMARK near the support zone of Rs 1397 to Rs 2208 for potential opportunities. A flag above Rs 2464 could suggest improving momentum toward Rs 2,800. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Glenmark Pharmaceuticals in FY27
A well-rounded Glenmark Pharmaceuticals analyst review must assess downside risks. Key risks for Glenmark Pharmaceuticals include a macro slowdown affecting Pharmaceuticals – Branded and Specialty sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in GLENMARK.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Glenmark Pharmaceuticals Analyst Review Verdict for 2026
This Glenmark Pharmaceuticals analyst review concludes that at Rs 2,324.10, GLENMARK offers a defined risk-reward with a consensus target of Rs 2,800. The 52-week range of Rs 1,370.00 to Rs 2,474.00 provides context on the current entry point. Use this Glenmark Pharmaceuticals analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on GLENMARK.
Frequently Asked Questions: Glenmark Pharmaceuticals Analyst Review 2026
What is the analyst target for Glenmark Pharmaceuticals in 2026?
The analyst consensus target is Rs 2,800, with a bull case of Rs 3,400 and a bear case of Rs 2,000. Monitor Q1 FY27 earnings for confirmation as highlighted in this Glenmark Pharmaceuticals analyst review.
Is Glenmark Pharmaceuticals a good investment at Rs 2,324.10?
At Rs 2,324.10 with a P/E of 18x and a consensus target of Rs 2,800, this Glenmark Pharmaceuticals analyst review is constructive for medium to long-term investors in the Pharmaceuticals – Branded and Specialty sector. Always consult a SEBI-registered advisor before investing.
What is Glenmark Pharmaceuticals’s 52-week high and low?
The 52-week high is Rs 2,474.00 and the 52-week low is Rs 1,370.00. At Rs 2,324.10, GLENMARK is positioned within this range as noted in this Glenmark Pharmaceuticals analyst review.
What are the key risks for Glenmark Pharmaceuticals?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – Branded and Specialty sector as assessed in this Glenmark Pharmaceuticals analyst review.
Where can I track live data for Glenmark Pharmaceuticals?
Track Glenmark Pharmaceuticals’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Glenmark Pharmaceuticals analyst review.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
